Parallax Volatility Advisers, L.P. Arbutus Biopharma Corp Transaction History

Parallax Volatility Advisers, L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.88 - $2.88 $330 - $506	176 Added 0.09%	200,528 $383,000
Q2 2022 Aug 15, 2022	SELL	$1.98 - $3.17 $106 - $171	-54 Reduced 0.03%	200,352 $543,000
Q1 2022 May 16, 2022	BUY	$2.42 - $3.98 $117,866 - $193,845	48,705 Added 32.11%	200,406 $597,000
Q4 2021 Feb 14, 2022	BUY	$3.11 - $4.61 $423,177 - $627,282	136,070 Added 870.51%	151,701 $590,000
Q3 2021 Nov 15, 2021	BUY	$2.65 - $4.62 $41,422 - $72,215	15,631 New	15,631 $67,000
Q1 2019 May 15, 2019	SELL	$3.41 - $4.57 $27,164 - $36,404	-7,966 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$3.5 - $9.66 $27,881 - $76,951	7,966 New	7,966 $31,000

155

99.5M

2.31M

525K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $478M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.